scholarly journals 714 An Evaluation of The Discontinuation of Tamsulosin and Finasteride Post Transurethral Resection of The Prostate (TURP) At UHL

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
S Bahri ◽  
B Malcomson ◽  
K Ball ◽  
D Bhrambhatt ◽  
J Beatty
Keyword(s):  
Transurethral Resection ◽  
Significant Proportion ◽  
Time Frame ◽  
Pharmacological Therapy ◽  
University Hospitals ◽  
Reductase Inhibitors ◽  
Urinary Tract Symptoms ◽  
Prostatic Enlargement ◽  
The University ◽  
5 Alpha Reductase Inhibitors

Abstract Aim A significant proportion of men suffer from lower urinary tract symptoms (LUTS) secondary to prostatic enlargement. If medical management of BPH fails surgical transurethral resection of the prostate maybe required. The continuation of pharmacological therapy post operatively is redundant, however it was noted that several patients remained on these medications post TURP. The aim of this project was to identify if patients following surgical intervention were discontinued from preexisting medications that became redundant post operatively. Method A retrospective analysis was performed of patients who underwent TURPs between July- December 2019 within the University Hospitals of Leicester NHS trust to assess if patients preexisting medications used for the treatment of LUTS were discontinued post operatively. Results In the above time frame, 104 TURPs were performed in the trust. Out of these, 89 men were already on 5-alpha reductase inhibitors and/or alpha blocker, predominantly tamsulosin and finasteride. Of the 89 men, only 46 were given a clear instruction to stop these drugs on discharge. Conclusions Continuation of the above medication is unnecessary post TURPs with potentially avoidable side effects for patients and an unnecessary expense. A series of changes were implemented to improve practice. These will be reevaluated on the recommencement of TURPs following the covid-19 pandemic.

scholarly journals Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors

Uro ◽  
2021 ◽  
Vol 1 (3) ◽  
pp. 82-98
Author(s):  
Antonio La Torre ◽  
Caterina Palleria ◽  
Irene Tamanini ◽  
Andrea Scardigli ◽  
Tommaso Cai ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Sexual Dysfunction ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Sexual Dysfunctions ◽  
Reductase Inhibitors ◽  
Urinary Tract Symptoms ◽  
5 Alpha Reductase Inhibitors ◽  
Lower Urinary

This is a critical review of the current literature data about sexual dysfunction as a potential side effect related to drugs commonly used for the treatment of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. In this narrative review, we analyzed data from the literature related to the development of sexual dysfunctions during the treatment of BPH or LUTS. Both α-blockers and 5-alpha reductase inhibitors (5-ARIs) can induce erectile dysfunction, ejaculatory disorders and a reduction in sexual desire. The sexual side effect profile of these drugs is different. Among the α-blockers, silodosin appears to have the highest incidence of ejaculatory disorders. Persistent sexual side effects after the discontinuation of finasteride have been recently reported; however, further studies are needed to clarify the true incidence and the significance of this finding. However, most of the published studies are affected by a weak methodology and other important limitations, with only a few RCTs available. Therefore, it is desirable that future studies will include validated tools to assess and diagnose the sexual dysfunction induced by these medications, especially for ejaculation and sexual desire disorders.

scholarly journals Drugs used in prostatic enlargement and lower urinary tract symptoms: unseen and overlooked effects on sexual health

2019 ◽  
Vol 9 (3) ◽  
pp. 240-247
Author(s):  
SM Ashrafuzzaman ◽  
Muhammad Abdur Rahim ◽  
Zafar Ahmed Latif
Keyword(s):  
Urinary Tract ◽  
Side Effects ◽  
Lower Urinary Tract Symptoms ◽  
Side Effect ◽  
Lower Urinary Tract ◽  
Reductase Inhibitors ◽  
Adrenergic Antagonist ◽  
Urinary Tract Symptoms ◽  
Prostatic Enlargement ◽  
Lower Urinary

Benign prostatic hyperplasia (BPH) is one of the most common genitourinary complications in men over 50 years of age and typically presents with lower urinary tract symptoms (LUTS) and may need medical and occasionally surgical interventions. Few of them may only need advice on behavioral modification like less water intake after sunset, avoid tea, coffee after evening, avoid alcohol and less use of diuretics. The symptoms related to BPH or LUTS without any prostatic enlargement are incomplete voiding, frequency, intermittency, urgency, weak stream, straining and nocturia. For most patients with mild to moderate symptoms of BPH [International Prostate Symptom Score (IPSS) <8 or 8-19 respectively] monotherapy with an á-1-adrenergic antagonist remains initial treatment. The choice of specific á-adrenergic antagonist agent is generally based on cost and side effect profile. Other classes of medications include 5á-reductase inhibitors and phosphodiesterase (PDE) 5 inhibitors. In men who have mild to moderate symptoms of BPH and concomitant erectile dysfunction (ED), PDE-5 inhibitors are reasonable alternative. Now a days á-1-adrenoceptor blockers and 5á-reductase inhibitors are often combined to give a synergistic effect. A review of the current literature identified several adverse sexual side effects, including ED, decreased libido, orgasmic disorders and ejaculatory disorders. It is important to know the extent of these side effects, as the clinician and patient will need to decide the cost of improved voiding symptoms. The prime adverse effect is ejaculatory disorders including the absence of ejaculation. Clinical consideration for BPH/LUTS should include the elements of male sexual function, patient’s age and the characteristics and comprehensive effects of each group of drugs. Methodological bias in clinical studies, such as the subjective evaluation of the sexual side effect makes it difficult to determine the ideal drug for treatment. Men without ED or irritant symptoms who desire medical therapy but cannot tolerate á-1-adrenergic antagonists and do not have predominately irritant symptoms or concomitant ED, treatment with a 5á-reductase inhibitor is a reasonable. Treatment for 6 to 12 months is generally needed before prostate size is sufficiently reduced to improve symptoms. Symptoms are usually reversible, so drugs may need to be continued for long time or indefinitely under supervision of specialist. Birdem Med J 2019; 9(3): 240-247

scholarly journals WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH

2019 ◽  
Vol 11 ◽  
pp. 175628721987953
Author(s):  
Ruth Kirschner-Hermanns ◽  
Petra Funk ◽  
Nadine Leistner
Keyword(s):  
Symptomatic Improvement ◽  
Root Extract ◽  
Double Blind ◽  
Synthetic Drugs ◽  
Adrenoceptor Antagonist ◽  
First Line Therapy ◽  
Reductase Inhibitors ◽  
Urinary Tract Symptoms ◽  
Prostatic Enlargement ◽  
Urtica Extract

Introduction: Lower urinary tract symptoms (LUTS) caused by prostatic enlargement are a common impairing condition in men aged 50 years and older. In the management of LUTS related to benign prostatic hyperplasia (BPH), medication, particularly by α-adrenoceptor antagonists, 5α-reductase inhibitors, and phytopharmaceuticals, is considered the first-line therapy. Despite their popularity, a number of adverse effects on the cardiovascular or cognitive systems have been reported for some of the synthetic drugs. One of the promising herbal preparations for the treatment of patients suffering from LUTS related to BPH is WS PRO 160 I 120 mg, a combination of sabal fruit extract and urtica root extract. Methods: This review of the literature summarizes clinical evidence for WS PRO 160 I 120 mg derived from four randomized placebo- or reference-controlled double-blind clinical trials including men aged 50 years and older. In all trials, symptomatic improvement was evaluated by the International Prostate Symptom Score (I-PSS) total score. Results: Treatment effects of WS PRO 160 I 120 mg were shown to be superior over placebo and comparable with the 5α-reductase inhibitor finasteride or the α1-adrenoceptor antagonist tamsulosin with more favorable tolerability and safety profiles as compared with the reference drugs. Conclusions: The results suggest WS PRO 160 I 120 mg to be considered as a valid alternative in the treatment of patients with early BPH, especially with view to sexual function and a good quality of life, especially in long-term use.

scholarly journals Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Undergoing Transurethral Resection of the Prostate (TURP)

2021 ◽  
Vol 31 (4) ◽  
pp. 4
Author(s):  
Zen Ary Prasetyo ◽  
Taufiq Nur Budaya ◽  
Besut Daryanto
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Urinary Retention ◽  
Transurethral Resection ◽  
The Elderly ◽  
Pharmacological Therapy ◽  
Prostatic Hyperplasia ◽  
Therapy Failure ◽  
Common Complaint ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

<p class="EnglishAbstract">Benign prostatic hyperplasia (BPH) is one of the most common diseases affecting the elderly, and Transurethral Resection of the Prostate (TURP) is a gold standard surgical procedure in BPH patients. Although the TURP rate is high, the publication of TURP profile data in Indonesia is still limited. This study aimed at determining the characteristics of BPH patients who underwent TURP at Saiful Anwar General Hospital. This study is a descriptive study by collecting data of 162 BPH patients who underwent TURP from January 2015 to August 2017. TURP is primarily performed in patients aged 61-70 years (39.5%). Recurrent urinary retention was the most common indication for the procedure (54.9%) followed by bladder stone (21%), pharmacological therapy failure (10.5%), inguinal hernia (8%), severe Lower Urinary Tract Symptoms (LUTS) (3.7%), and renal insufficiency (1.9%). As many as 58% of patients who underwent TURP had a prostate volume higher than 50 ml. Urinary retention is the most common complaint among BPH patients who underwent TURP, and recurrent urinary retention is the most common TURP indicator. </p>

Sign in / Sign up

Export Citation Format

Share Document